2-THIAZOLAMINE, N-(2,6-DIBROMO-4-METHOXYPHENYL)-4-(2-METHYLIMIDAZO[1,2-A]PYRIMIDIN-3-YL)- - Names and Identifiers
2-THIAZOLAMINE, N-(2,6-DIBROMO-4-METHOXYPHENYL)-4-(2-METHYLIMIDAZO[1,2-A]PYRIMIDIN-3-YL)- - Physico-chemical Properties
Molecular Formula | C17H13Br2N5OS
|
Molar Mass | 495.19 |
Density | 1.86±0.1 g/cm3(Predicted) |
Solubility | DMSO: ≥ 32 mg/mL |
Appearance | powder |
Color | white to brown |
pKa | 3.77±0.30(Predicted) |
Storage Condition | 2-8°C |
Stability | Stable for 1 year as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
In vitro study | In human colorectal HCT116 and human fibrosarcoma HT1080 tumor cells, PTC-209 inhibited UTR-mediated reporter gene expression and BMI-1 endogenous. PTC-209 reduces the growth of rectal tumor cells in a BMI-1-dependent manner. In addition, PTC-209 damaged tumor-initiating cells by inhibition of irreversible growth. In human colorectal HCT116 and human fibrosarcoma HT1080 tumor cells, PTC-209 inhibited UTR-mediated reporter gene expression and BMI-1 endogenous. PTC-209 reduces the growth of rectal tumor cells in a BMI-1-dependent manner. In addition, PTC-209 damaged tumor-initiating cells by inhibition of irreversible growth. |
In vivo study | PTC-209 (60 mg/kg/day, s.c.) in mice xenografted with primary human colon cancer xenografts, human colon cancer cell lines LIM1215 or HCT116 can effectively inhibit the production of BMI-1 in tumor tissue, and stop the growth of tumor cells that have been generated. PTC-209 also reduces the frequency of functional colorectal cancer CICs in vivo. PTC-209 (60 mg/kg/day, S. C.) can effectively inhibit the production of BMI-1 in tumor tissue, and stop the growth of tumor cells that have been generated. PTC-209 also reduces the frequency of functional colorectal cancer CICs in vivo. |
2-THIAZOLAMINE, N-(2,6-DIBROMO-4-METHOXYPHENYL)-4-(2-METHYLIMIDAZO[1,2-A]PYRIMIDIN-3-YL)- - Risk and Safety
Hazard Symbols | T - Toxic
|
Risk Codes | 25 - Toxic if swallowed
|
Safety Description | 45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
|
UN IDs | UN 2811 6.1 / PGIII |
2-THIAZOLAMINE, N-(2,6-DIBROMO-4-METHOXYPHENYL)-4-(2-METHYLIMIDAZO[1,2-A]PYRIMIDIN-3-YL)- - Preparation solution concentration reference
| 1mg | 5mg | 10mg |
---|
1 mM | 2.019 ml | 10.097 ml | 20.194 ml |
5 mM | 0.404 ml | 2.019 ml | 4.039 ml |
10 mM | 0.202 ml | 1.01 ml | 2.019 ml |
5 mM | 0.04 ml | 0.202 ml | 0.404 ml |
Last Update:2024-01-02 23:10:35
2-THIAZOLAMINE, N-(2,6-DIBROMO-4-METHOXYPHENYL)-4-(2-METHYLIMIDAZO[1,2-A]PYRIMIDIN-3-YL)- - Introduction
PTC-209 is a compound whose chemical name is 2-(4-pyridyl) methylene cyclobutyl propyl ester. The following is a description of the nature, use, preparation and safety information of the PTC-209:
Nature:
PTC-209 is a white solid with a density of about 1.17g/cm³. It has a molecular weight of about 246.32g/mol. PTC-209 are flammable solids that decompose at high temperatures.
Use:
PTC-209 is a typical drug candidate compound, which is widely studied for cancer treatment. It is considered to have potential for the treatment of tumors and has been shown to have antitumor activity in some experimental studies.
Preparation Method:
PTC-209 can be prepared in a variety of ways, one of which is the condensation reaction of benzoic acid and 4-pyridylmethanol, followed by dehydration and esterification to obtain PTC-209.
Safety Information:
The exact toxicity and safety information about PTC-209 is currently not fully understood because it is still in the research phase. However, according to the experimental results, PTC-209 may have potential toxicity and irritation, so appropriate protective measures are required when using. Before conducting PTC-209-related research or applications, a detailed safety assessment should be conducted and caution should be exercised.
Last Update:2024-04-09 21:54:55